{"id":"W83713607","doi":"10.2165/11587890-000000000-00000","title":"The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis","year":2011,"lang":"en","type":"review","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":74,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Western University","funders":"Allergan; Genentech; LEO Pharma; Medac; Mitsubishi Tanabe Pharma Corporation; Cilag; Astellas Pharma; Novo Nordisk; Incyte; University of Connecticut; Abbott Laboratories; Zalicus; Biogen; Celgene; Amgen; Pfizer; Galderma; Eli Lilly and Company; GlaxoSmithKline; Eisai","keywords":"Adalimumab; Medicine; Adverse effect; Psoriasis; Placebo; Population; Clinical trial; Internal medicine; Dosing; Incidence (geometry); Dermatology; Pathology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009068361,0.0005862849,0.006175038,0.0003493132,0.0001189571,0.00001031866,0.0008674484,0.0006195624,0.0001093934],"category_scores_gemma":[0.0003792599,0.0003300969,0.00179136,0.0004198911,0.0008151295,0.00005765078,0.000127181,0.0007079658,0.0001900064],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001217577,"about_ca_system_score_gemma":0.001112581,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009337554,"about_ca_topic_score_gemma":0.0002036772,"domain_scores_codex":[0.9907153,0.003789804,0.004416958,0.0004219813,0.00007148864,0.0005845019],"domain_scores_gemma":[0.9908939,0.004460244,0.003674144,0.0006515959,0.0001889813,0.0001311392],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00202391,0.0005075529,0.003385182,0.0001832262,0.003150231,0.0002387095,0.0001518681,9.518718e-7,3.992232e-7,0.0001375321,0.000187256,0.9900332],"study_design_scores_gemma":[0.00418593,0.003072632,0.003450037,0.002166491,0.00327837,0.005813514,0.0001126075,1.404889e-7,0.00002741567,0.00004821555,0.9774058,0.0004388703],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01467498,0.9819727,0.00003824503,0.000237362,0.002141107,0.0005789456,0.00008823605,0.00001065785,0.0002577853],"genre_scores_gemma":[0.01373738,0.9854857,0.0001467344,0.00008372801,0.0001135383,0.00004398874,0.0000369557,0.00004640155,0.0003055699],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9895943,"threshold_uncertainty_score":0.9999151,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07252126911291348,"score_gpt":0.3763919246789039,"score_spread":0.3038706555659905,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}